CytomX Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring on June 17, 2026, and June 22, 2026, surrounding CytomX Therapeutics, Inc.'s 2026 Annual Meeting of Stockholders. The filing details the approval of corporate governance amendments, equity plan modifications, and the election of directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting results rather than financial performance metrics.
Material Changes and Corporate Actions
- Equity Plan Amendments: Stockholders approved increasing the authorized shares under the 2015 Equity Incentive Plan by 6,500,000 shares and the Employee Stock Purchase Plan (ESPP) by 1,000,000 shares.
- Charter Amendment: On June 22, 2026, the Company filed a Certificate of Amendment to increase authorized common stock from 300,000,000 to 600,000,000 shares.
- Director Elections: Class II director nominees Matthew P. Young and Elaine V. Jones, Ph.D., were elected to the Board.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results and Management Commentary
At the Annual Meeting, 183,604,084 shares were voted out of 217,702,919 outstanding. Key voting outcomes included:
- Proposal 3 (Charter Amendment): Approved with 178,362,995 votes FOR, 4,771,689 AGAINST, and 469,400 ABSTAIN.
- Proposal 4 (Equity Plan): Approved with 147,079,951 votes FOR, 1,745,001 AGAINST, and 180,010 ABSTAIN.
- Proposal 5 (ESPP): Approved with 147,375,197 votes FOR, 1,468,576 AGAINST, and 161,189 ABSTAIN.
- Proposal 6 (Say-on-Pay): Approved with 147,127,715 votes FOR, 1,722,679 AGAINST, and 154,568 ABSTAIN.
- Proposal 7 (Frequency of Say-on-Pay): Stockholders voted for an annual advisory vote (145,004,404 votes for 1 year).
Notably, there were 34,599,122 broker non-votes recorded for proposals involving director elections and equity plan amendments.
Investor Verification Checklist
- Verify the impact of the 6.5 million share increase in the 2015 Equity Incentive Plan on potential future dilution.
- Confirm the effective date of the Charter Amendment increasing authorized shares to 600 million.
- Review the Definitive Proxy Statement (filed April 30, 2026) for detailed terms of the equity plan amendments.
- Monitor the Company's capital allocation strategy given the significant increase in authorized share capacity.